FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367673665> ?p ?o ?g. }

• W4367673665 abstract "Abstract Funding Acknowledgements Type of funding sources: Foundation. Main funding source(s): Novo Nordisk Fonden Background Cardiogenic shock (CS) is seen in up to 10% of patients with ST-elevation myocardial infarction (STEMI) and is associated with a high mortality rate of up to 50%. Approximately 1/3 of STEMI-patients developing CS are not in overt shock at time of hospital admission but will develop hemodynamical instability within the following hours to days. Patients at risk of CS development may be clinically stable but with normal lactate levels (Society for Cardiovascular Angiography and Interventions classification, SCAI A/B). The Observatoire Régional Breton sur l'Infarctus (ORBI) clinical risk score has recently been developed and validated for predicting the risk of in-hospital (late) CS. STEMI-patients with an ORBI score &gt;=10 have a risk of in-hospital CS development of more than 8-10%. NTproBNP is a biomarker released from the myocardium reflecting neurohormonal activation which is strongly correlated with hemodynamic parameters. Neurohormonal activation as well as a systemic inflammatory response are present acutely at hospital admission in STEMI patients developing late CS compared to non-CS patients suggesting an early subclinical hemodynamic deterioration. Dobutamine induces significant positive inotropic- and dose-dependent chronotropic effects and decreases afterload by peripheral vasodilatation, which increases cardiac output and organ perfusion. The interleukin-6 receptor antagonist Tocilizumab has been shown to reduce troponin leakage and increase myocardial salvage in acute MI patients. The effects of Dobutamine and Tocilizumab in a high-risk population have not previously been investigated. Methods DOBERMANN is an investigator-initiated, double blinded randomized clinical trial. Consecutive patients with acute MI admitted for acute coronary angiography and treated with percutaneous coronary intervention are screened with the ORBI risk score in the catheterization laboratory. One hundred adult patients presenting without CS at hospital admission with an intermediate-high risk of CS development (ORBI risk score of &gt;=10) will be randomized 2x2 to receive a continuous intravenous infusion of dobutamine (5 micrograms/kg/minute, 24h) vs. placebo, and a single dose of Tocilizumab (280 mg, 1h) vs. placebo. NTproBNP as a proxy for development of CS and hemodynamic instability will be sampled for primary endpoint analysis. Effects on clinical parameters, mortality, morbidity as well as specific indicators of inflammation, cardiac function, and infarct size will secondarily be assessed noninvasively at 48h and at three months follow-up. Enrollment began in March 2022 and is commencing as planned. Discussion We hypothesize that inflammatory and neurohormonal responses are associated with subclinical hemodynamic instability in patients with AMI with intermediate/high risk of CS. The potentially unstable condition may be targeted pharmacologically as an add-on to existing therapy." @default.
• W4367673665 created "2023-05-03" @default.
• W4367673665 creator A5004274470 @default.
• W4367673665 creator A5005800831 @default.
• W4367673665 creator A5007737813 @default.
• W4367673665 creator A5008691276 @default.
• W4367673665 creator A5014707937 @default.
• W4367673665 creator A5030735913 @default.
• W4367673665 creator A5034841594 @default.
• W4367673665 creator A5036410890 @default.
• W4367673665 creator A5048850171 @default.
• W4367673665 creator A5053038885 @default.
• W4367673665 creator A5061968472 @default.
• W4367673665 creator A5064896773 @default.
• W4367673665 creator A5066697520 @default.
• W4367673665 creator A5069905953 @default.
• W4367673665 creator A5091743497 @default.
• W4367673665 date "2023-05-01" @default.
• W4367673665 modified "2023-09-26" @default.
• W4367673665 title "Low-dose dobutamine infusion and single-dose tocilizumab in acute myocardial infarction patients with high risk of cardiogenic shock development - rationale and design of the DOBERMANN trial" @default.
• W4367673665 doi "https://doi.org/10.1093/ehjacc/zuad036.131" @default.
• W4367673665 hasPublicationYear "2023" @default.
• W4367673665 type Work @default.
• W4367673665 citedByCount "0" @default.
• W4367673665 crossrefType "journal-article" @default.
• W4367673665 hasAuthorship W4367673665A5004274470 @default.
• W4367673665 hasAuthorship W4367673665A5005800831 @default.
• W4367673665 hasAuthorship W4367673665A5007737813 @default.
• W4367673665 hasAuthorship W4367673665A5008691276 @default.
• W4367673665 hasAuthorship W4367673665A5014707937 @default.
• W4367673665 hasAuthorship W4367673665A5030735913 @default.
• W4367673665 hasAuthorship W4367673665A5034841594 @default.
• W4367673665 hasAuthorship W4367673665A5036410890 @default.
• W4367673665 hasAuthorship W4367673665A5048850171 @default.
• W4367673665 hasAuthorship W4367673665A5053038885 @default.
• W4367673665 hasAuthorship W4367673665A5061968472 @default.
• W4367673665 hasAuthorship W4367673665A5064896773 @default.
• W4367673665 hasAuthorship W4367673665A5066697520 @default.
• W4367673665 hasAuthorship W4367673665A5069905953 @default.
• W4367673665 hasAuthorship W4367673665A5091743497 @default.
• W4367673665 hasBestOaLocation W43676736651 @default.
• W4367673665 hasConcept C126322002 @default.
• W4367673665 hasConcept C155710745 @default.
• W4367673665 hasConcept C158328960 @default.
• W4367673665 hasConcept C164705383 @default.
• W4367673665 hasConcept C178853913 @default.
• W4367673665 hasConcept C2776850375 @default.
• W4367673665 hasConcept C2777953023 @default.
• W4367673665 hasConcept C2778198053 @default.
• W4367673665 hasConcept C2781185063 @default.
• W4367673665 hasConcept C2908647359 @default.
• W4367673665 hasConcept C500558357 @default.
• W4367673665 hasConcept C71924100 @default.
• W4367673665 hasConcept C84393581 @default.
• W4367673665 hasConcept C99454951 @default.
• W4367673665 hasConceptScore W4367673665C126322002 @default.
• W4367673665 hasConceptScore W4367673665C155710745 @default.
• W4367673665 hasConceptScore W4367673665C158328960 @default.
• W4367673665 hasConceptScore W4367673665C164705383 @default.
• W4367673665 hasConceptScore W4367673665C178853913 @default.
• W4367673665 hasConceptScore W4367673665C2776850375 @default.
• W4367673665 hasConceptScore W4367673665C2777953023 @default.
• W4367673665 hasConceptScore W4367673665C2778198053 @default.
• W4367673665 hasConceptScore W4367673665C2781185063 @default.
• W4367673665 hasConceptScore W4367673665C2908647359 @default.
• W4367673665 hasConceptScore W4367673665C500558357 @default.
• W4367673665 hasConceptScore W4367673665C71924100 @default.
• W4367673665 hasConceptScore W4367673665C84393581 @default.
• W4367673665 hasConceptScore W4367673665C99454951 @default.
• W4367673665 hasIssue "Supplement_1" @default.
• W4367673665 hasLocation W43676736651 @default.
• W4367673665 hasOpenAccess W4367673665 @default.
• W4367673665 hasPrimaryLocation W43676736651 @default.
• W4367673665 hasRelatedWork W1904285445 @default.
• W4367673665 hasRelatedWork W2012572848 @default.
• W4367673665 hasRelatedWork W2058479509 @default.
• W4367673665 hasRelatedWork W2127720381 @default.
• W4367673665 hasRelatedWork W2135619337 @default.
• W4367673665 hasRelatedWork W2161091896 @default.
• W4367673665 hasRelatedWork W2409437273 @default.
• W4367673665 hasRelatedWork W2416093147 @default.
• W4367673665 hasRelatedWork W2436945226 @default.
• W4367673665 hasRelatedWork W2768555270 @default.
• W4367673665 hasVolume "12" @default.
• W4367673665 isParatext "false" @default.
• W4367673665 isRetracted "false" @default.
• W4367673665 workType "article" @default.